KRAS and cancer: In a variety of KRASG12C, KRASG12V, and KRASG12D cancer lines, MP-3995 blocked pERK signaling in the low micromolar range (Fig. 4A), thus demonstrating this molecule is a pan-KRAS inhibitor.